Search:        >> Advanced Search
Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lynch, C. M. Articles by Thurberg, B. L. Search for Related Content PubMed PubMed Citation Articles by Lynch, C. M. Articles by Thurberg, B. L. Social Bookmarking                      What's this?

High-resolution Light Microscopy (HRLM) and Digital Analysis of Pompe Disease Pathology

Colleen M. Lynch, Jennifer Johnson, Charles Vaccaro and Beth L. Thurberg

Department of Pathology, Genzyme Corporation, Framingham, Massachusetts

Correspondence to: Beth L. Thurberg, MD, PhD, Department of Pathology, Genzyme Corporation, One Mountain Road, Framingham, MA 01701-9322. E-mail: Beth.Thurberg{at}genzyme.com

Pompe disease is an autosomal recessive lysosomal storage disorder caused by a deficiency of the lysosomal enzyme acid -glucosidase, responsible for the degradation of lysosomal glycogen. Absent or low levels of the enzyme leads to lysosomal glycogen accumulation in cardiac and skeletal muscle cells, resulting in progressive muscle weakness and death from cardiac or respiratory failure. Recombinant enzyme replacement and gene therapy are now being investigated as treatment modalities for this disease. A knockout mouse model for Pompe disease, induced by the disruption of exon 6 within the acid -glucosidase gene, mimics the human disease and has been used to evaluate the efficacy of treatment modalities for clearing glycogen. However, for accurate histopathological assessment of glycogen clearance, maximal preservation of in situ lysosomal glycogen is essential. To improve retention of glycogen in Pompe tissues, several fixation and embedding regimens were evaluated. The best glycogen preservation was obtained when tissues fixed with 3% glutaraldehyde and postfixed with 1% osmium tetroxide were processed into epon–araldite. Preservation was confirmed by staining with the Periodic acid–Schiff's reaction and by electron microscopy. This methodology resulted in high-resolution light microscopy (HRLM) sections suitable for digital quantification of glycogen content in heart and skeletal muscle. Combining this method of tissue fixation with computer-assisted histomorphometry has provided us with what we believe is the most objective and reproducible means of evaluating histological glycogen load in Pompe disease.

(J Histochem Cytochem 53:63–73, 2005)

Key Words: Pompe disease • glycogen storage disease • type 2 • histological glycogen • preservation • Periodic acid–Schiff's reaction • vacuolar myopathy • histomorphometry • epon–araldite • electron microscopy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. V. Taksir, D. Griffiths, J. Johnson, S. Ryan, L. S. Shihabuddin, and B. L. Thurberg Optimized Preservation of CNS Morphology for the Identification of Glycogen in the Pompe Mouse Model J. Histochem. Cytochem., October 1, 2007; 55(10): 991 - 998. [Abstract] [Full Text] [PDF]

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact

The Journal of Histochemistry & Cytochemistry is owned, published, and licensed by The Histochemical Society © 2005